Special issue “Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications” focuses on the latest challenges and achievements in using metabolomics to diagnose diseases and monitor patients after treatment
MORRISVILLE, N.C., Jan. 28, 2025 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces the Multidisciplinary Digital Publishing Institute (MDPI) selects Metabolon scientists Dr. Adam Kennedy and Dr. Greg Michelotti to guest edit MDPI’s Metabolites journal.
The special issue, “Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications,” focuses on the latest challenges and achievements in metabolomics for diagnosing diseases and monitoring patients after treatment. This issue will include clinical studies and basic research using animal and cellular models to showcase recent developments in the field.
“Metabolomics places the functional output of the genome and the proteome into the hands of scientists and clinicians so that systems and patient phenotypes can be interrogated. Sourcing data from the genetic background, environmental inputs, and lifestyle changes brings clarity to the phenotype of an individual,” said Dr. Adam Kennedy, Director of Clinical Metabolomics. “We want to ensure this science is showcased so the full effect of metabolomics can be leveraged in pre-clinical, clinical, and research segments.”
“Not many people can edit a leading scientific journal like this – it’s challenging. That two of our scientists were asked to be senior editors speaks to Metabolon’s deep well of scientific talent,” said Ro Hastie, Metabolon CEO.
If you are interested in contributing to this MDPI Metabolites Journal Special Issue, the deadline for manuscript submissions is July 1, 2025. For more information, please visit: https://www.mdpi.com/journal/metabolites/special_issues/IB1EP0Q098
About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,500+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
SOURCE Metabolon, Inc.
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…